Sensus HealthcareSRTS
SRTS
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1,600% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 1
1,068% more call options, than puts
Call options by funds: $222K | Put options by funds: $19K
170% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 10
50% more capital invested
Capital invested by funds: $22.6M [Q3] → $33.9M (+$11.3M) [Q4]
30% more funds holding
Funds holding: 50 [Q3] → 65 (+15) [Q4]
6.21% more ownership
Funds ownership: 23.71% [Q3] → 29.92% (+6.21%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
156%
upside
Avg. target
$12.50
167%
upside
High target
$13
177%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Ben Haynor 44% 1-year accuracy 4 / 9 met price target | 177%upside $13 | Buy Maintained | 11 Mar 2025 |
HC Wainwright & Co. Yi Chen 46% 1-year accuracy 74 / 162 met price target | 156%upside $12 | Buy Maintained | 10 Feb 2025 |
Financial journalist opinion
Based on 6 articles about SRTS published over the past 30 days
Neutral
Zacks Investment Research
6 hours ago
Sensus Healthcare, Inc. (SRTS) Rises As Market Takes a Dip: Key Facts
Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $4.69, moving +1.08% from the previous trading session.

Positive
Zacks Investment Research
1 week ago
Here's Why Sensus Healthcare, Inc. (SRTS) Gained But Lagged the Market Today
Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $4.78, moving +0.84% from the previous trading session.

Neutral
Business Wire
2 weeks ago
Sensus Healthcare to Participate in the 37th Annual ROTH Conference
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it will be participating in Roth Capital's 37th Annual ROTH Conference, being held March 17-18 in Dana Point, California. Management will be holding one-on-one meetings with registered investors during the conference. Registered attendees.

Neutral
Zacks Investment Research
2 weeks ago
Brokers Suggest Investing in Sensus Healthcare (SRTS): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Neutral
Business Wire
3 weeks ago
Sensus Healthcare to Showcase Commercial and Late-Stage Products at the American Academy of Dermatology Annual Meeting
BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it will be showcasing its full line of commercial Superficial Radiotherapy (SRT) products including the SRT-100®, SRT-100+ and SRT-100 Vision™ systems, along with several innovative pre-commercial products, at the 2025 American Academy of.

Neutral
Business Wire
3 weeks ago
Sensus Healthcare Announces Publication of Study at Tri Service Military Hospital in Taiwan Demonstrating Efficacy of SRT-100® in Preventing Keloid Recurrence
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the publication of a study titled "Keloid Excision With Primary Closure Combined With Superficial Radiation Therapy (SRT-100)" in the Annals of Plastic Surgery. The single-site, retrospective study evaluated the clinical outcomes of combin.

Neutral
Business Wire
1 month ago
Sensus Healthcare Buys Back Shares
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that the company has resumed purchasing shares of its common stock in open-market transactions under a $3.0 million share repurchase program approved by its Board of Directors and announced in August 2023. “We are implementing this program.

Neutral
Seeking Alpha
1 month ago
Sensus Healthcare: A Tough Q1 2025 Awaits Ahead
Q4 2024 showed a significant miss in profitability despite a 4% YoY sales growth; gross profit margin dropped due to a one-time discount for a new big client. The FDA initiatives are interesting, but they will bring a slowdown in sales as they are fully rolled out. Management has warned of a Q1 2025 with considerably lower sales due to the Fair Deal Agreements and seasonal factors.

Neutral
Seeking Alpha
1 month ago
Sensus Healthcare, Inc. (SRTS) Q4 2024 Earnings Call Transcript
Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q4 2024 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Tirth Patel - Alliance Advisors, IR Joe Sardano - Chairman and CEO Michael Sardano - President & General Counsel Javier Rampolla - CFO Conference Call Participants Jeremy Pearlman - Maxim Group Arsalan Cameron - Roth Capital Partners Ben Haynor - Lake Street Capital Markets Operator Good day, and welcome to the Sensus Healthcare Fourth Quarter 2024 Financial Results Conference Call. [Operator Instructions].

Negative
Zacks Investment Research
1 month ago
Sensus Healthcare, Inc. (SRTS) Lags Q4 Earnings Estimates
Sensus Healthcare, Inc. (SRTS) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.26 per share a year ago.

Charts implemented using Lightweight Charts™